about
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Perspectives on Self-Advocacy: Comparing Perceived Uses, Benefits, and Drawbacks Among Survivors and ProvidersOutcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage eraNovel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteomeProteomic Analysis of Matched Formalin-Fixed, Paraffin-Embedded Specimens in Patients with Advanced Serous Ovarian CarcinomaStrategies for ovarian cancer prevention.The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group studyClassification of ovarian cancer: a genomic analysis.Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.Preoperative high dose rate brachytherapy for clinical stage II endometrial carcinoma.Definitive radiation therapy for endometrial cancer in medically inoperable elderly patients.Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence.Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.Editorial: Inhibiting PARP as a Strategic Target in Cancer.Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation.A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer.Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease?Heavy cervical cancer burden in elderly women: how can we improve the situation?The Female Self-Advocacy in Cancer Survivorship Scale: A validation study.Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment.Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.Challenges in recruiting African-American women for a breast cancer genetics study.Germline pathogenic variants identified in women with ovarian tumorsBRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancerIntraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient OutcomesMetastatic Ovarian Serous Carcinoma Presenting as Inflammatory Breast Cancer: A Case ReportHigh-Dose-Rate Rotte “Y” Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year ResultsUse of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovaryAdvancing our understanding of endometrial cancer histologic subtypes: Should we lump or split?Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial CancerPublisher Correction: Shared heritability and functional enrichment across six solid cancersAssociation of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and AggressivenessPhase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
P50
Q30252854-52E3BACB-FF38-4482-8A6D-0A36B7F84849Q31043651-FE531C07-C8C5-42B3-B872-15A0AC3B7B97Q33873027-4C7441F1-64B9-4199-8207-09C228871B4AQ34045769-4B5F2B20-0AB1-42E2-B2B9-17997772FE53Q35308231-7F79AACF-00F3-4E7E-AFCC-9D4FBBC0BF5DQ36294598-003089B7-E18E-4096-990E-6812451F74B5Q37025580-7ACBCC5D-5A3D-4799-96D2-0AFD5BF16C0FQ37148143-057DA03E-A5DA-4113-863A-DAC52E599A8AQ37188831-5E29D569-A5DC-4E1B-A1BD-3670BE61AC8AQ37410472-E99C8647-F4F1-4C2B-94FB-0C66650F691CQ37426338-FDC503E0-47E7-4C25-9011-ABB30FEDF678Q37685383-D029A708-FBC1-471B-AB7C-0CE3F1F4B482Q38207399-C24B00DD-AFC7-41B8-A4A6-188E2911814EQ38640225-AA072D84-09ED-4E61-A194-1DC0F5EC90B6Q39724479-6487410F-17CA-4F93-B23E-2A3CB96AC331Q40182624-B2222148-ACF4-4A82-BBB1-85D28FAC49BCQ40814914-8EC83758-0B80-4B61-8FF7-93FF4057423AQ43230496-D28FA0F7-B359-42F7-97E8-4D90A595D8BDQ43779832-9F9F175D-496B-4E61-A686-99EDD9B9D6D8Q44259965-BC36601D-17AD-4967-B3DE-748C5F990D61Q45198129-1A3D2548-0E58-44AB-9FE8-27AD955EE4DDQ45339751-22910ADF-36F4-4718-87C2-FB0A0D578A9DQ47585985-6E0CA266-C01C-4E08-B4C4-FFADDDA0DDBBQ51669948-6A222541-001B-44C5-A87B-D2ABD5F00261Q53452808-A1704372-9FF4-4B6D-A093-BD090A4CA81CQ53453814-33079584-2C0C-4497-855E-1C876A087DF8Q53505559-5ADE2BDD-8465-4C4B-9125-DDC71DD8B804Q53682148-0FAC784D-E2A0-4A1A-8025-D88FE3E45711Q57471064-B3F01DE8-3213-41F0-903B-7D5A11F05512Q62112707-E37F4E55-EB9F-4B93-8981-71A72C5CB3B0Q62112708-5BBBAC0D-EBA2-4907-A702-B88F625586CAQ62112710-AA11947F-85F5-4A3E-BE11-EB98DC8E588EQ62112712-76E274E1-5834-4478-A8D7-69CFBD12DC19Q62112713-89555463-9E00-4AF2-8B21-EF6586B86EB5Q62112714-C9C2B074-4642-41C4-AC16-9A6741DE5768Q62112715-73E75B84-EF42-4742-BF62-0F190034FF8FQ90242034-64D02F90-9F40-4923-85A7-744816A8518CQ91271723-9A3345DF-5BFD-42A9-B98E-479E1A73ED40Q91327123-E158BE5F-2A21-4855-8DCD-1EBFEE2C787E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kristin K Zorn
@ast
Kristin K Zorn
@en
Kristin K Zorn
@es
Kristin K Zorn
@nl
Kristin K Zorn
@sl
كريستين كي زورن
@ar
type
label
Kristin K Zorn
@ast
Kristin K Zorn
@en
Kristin K Zorn
@es
Kristin K Zorn
@nl
Kristin K Zorn
@sl
كريستين كي زورن
@ar
altLabel
Kristin K. Zorn
@en
prefLabel
Kristin K Zorn
@ast
Kristin K Zorn
@en
Kristin K Zorn
@es
Kristin K Zorn
@nl
Kristin K Zorn
@sl
كريستين كي زورن
@ar
P106
P21
P31
P496
0000-0003-2143-8979